Save time and jump to the most important pieces.
Date | Price Target | Rating | Analyst |
---|---|---|---|
1/3/2023 | $5.00 | In-line | Evercore ISI |
2/24/2022 | $15.00 → $12.00 | Buy | Citigroup |
9/22/2021 | Outperform → Market Perform | Raymond James | |
8/4/2021 | $11.00 → $12.50 | Outperform | Raymond James |
6/28/2021 | $12.00 → $11.00 | Outperform | Raymond James |
BETHLEHEM, Pa., Nov. 18, 2024 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ:OSUR) announced today that the company is scheduled to participate in the following investor conference: Stephens Annual Investment Conference on Wednesday, November 20, with a Q&A session scheduled for 1 p.m. ET A live webcast and replay of the Q&A session will be available on the investor relations page of OraSure's website at https://orasure.gcs-web.com/events-and-presentations. The webcast will be archived on OraSure's website and will be available for approximately 90 days. About OraSure Technologies, Inc. OraSure Technologies, Inc. ("OraSure") transforms health through actionable insight and power
Q3 GAAP EPS of $(0.06); Q3 Non-GAAP EPS of $(0.01) OraQuick® HCV Self-test receives initial orders following receipt of WHO pre-qualification status Expanding Sample Management applications into blood proteomics Exiting Risk Assessment testing business to focus on markets with attractive growth opportunities BETHLEHEM, Pa., Nov. 06, 2024 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ:OSUR), a leader in point-of-care and home diagnostic tests and sample management solutions, today announced its financial results for the three months ended September 30, 2024. "Our Q3 results were consistent with our expectations, and we continue to make progress on our strategic transformation.
BETHLEHEM, Pa., Oct. 22, 2024 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ:OSUR) has scheduled its regular earnings conference call covering third quarter 2024 financial results and certain business developments for 5 p.m. ET on November 6, 2024. A webcast of the conference call will be available on the investor relations page of OraSure's website at https://orasure.gcs-web.com/events-and-presentations. Please click on the webcast link and follow the prompts for registration and access at least 10 minutes prior to the call. The webcast will be archived on OraSure's website shortly after the call has ended and will be available for approximately 90 days. For participants interes
Evercore ISI resumed coverage of OraSure with a rating of In-line and set a new price target of $5.00
Citigroup reiterated coverage of OraSure Technologies with a rating of Buy and set a new price target of $12.00 from $15.00 previously
Raymond James downgraded OraSure Technologies from Outperform to Market Perform
SC 13G/A - ORASURE TECHNOLOGIES INC (0001116463) (Subject)
SC 13G/A - ORASURE TECHNOLOGIES INC (0001116463) (Subject)
SC 13G - ORASURE TECHNOLOGIES INC (0001116463) (Subject)
10-Q - ORASURE TECHNOLOGIES INC (0001116463) (Filer)
8-K - ORASURE TECHNOLOGIES INC (0001116463) (Filer)
8-K - ORASURE TECHNOLOGIES INC (0001116463) (Filer)
4 - ORASURE TECHNOLOGIES INC (0001116463) (Issuer)
3 - ORASURE TECHNOLOGIES INC (0001116463) (Issuer)
4 - ORASURE TECHNOLOGIES INC (0001116463) (Issuer)
Q3 GAAP EPS of $(0.06); Q3 Non-GAAP EPS of $(0.01) OraQuick® HCV Self-test receives initial orders following receipt of WHO pre-qualification status Expanding Sample Management applications into blood proteomics Exiting Risk Assessment testing business to focus on markets with attractive growth opportunities BETHLEHEM, Pa., Nov. 06, 2024 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ:OSUR), a leader in point-of-care and home diagnostic tests and sample management solutions, today announced its financial results for the three months ended September 30, 2024. "Our Q3 results were consistent with our expectations, and we continue to make progress on our strategic transformation.
BETHLEHEM, Pa., Oct. 22, 2024 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ:OSUR) has scheduled its regular earnings conference call covering third quarter 2024 financial results and certain business developments for 5 p.m. ET on November 6, 2024. A webcast of the conference call will be available on the investor relations page of OraSure's website at https://orasure.gcs-web.com/events-and-presentations. Please click on the webcast link and follow the prompts for registration and access at least 10 minutes prior to the call. The webcast will be archived on OraSure's website shortly after the call has ended and will be available for approximately 90 days. For participants interes
Q2 GAAP EPS of $(0.01); Q2 Non-GAAP EPS of $0.07 OraQuick® HCV Self-test is the first globally to earn WHO pre-qualification Strong momentum with Syphilis Health Check™ launch Expanding Sample Management applications into saliva-based liquid biopsy BETHLEHEM, Pa., Aug. 06, 2024 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ:OSUR), a leader in point-of-care and home diagnostic tests and sample management solutions, today announced its financial results for the three months ended June 30, 2024. "Our team continues to execute well, delivering Q2 results that were near the top end of our revenue guidance range. Our second quarter Core revenue showed sequential improvement, and we
NEW YORK, June 7, 2024 /PRNewswire/ -- S&P Dow Jones Indices ("S&P DJI") will make the following changes to the S&P 500, S&P MidCap 400, and S&P SmallCap 600 indices effective prior to the open of trading on Monday, June 24, to coincide with the quarterly rebalance. The changes ensure each index is more representative of its market capitalization range. All companies being added to the S&P 500 are more representative of the large-cap market space, all companies being added to the S&P MidCap 400 are more representative of the mid-cap market space, and all companies being added to the S&P SmallCap 600 are more representative of the small-cap market space. The companies being removed from the S
Former Head of OraSure Technologies Joins at Key Stage Leading up to Company's Product Launch NOWDiagnostics (NOWDx), a developer of over-the-counter (OTC) and point-of-care (POC) diagnostics tests and first-in-class technology and platforms, today announced the appointment of Dr. Stephen S. Tang, Ph.D., MBA, as the chairman of the company's board of directors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240321747977/en/NOWDiagnostics (NOWDx) Welcomes Dr. Stephen S. Tang as Chairman of the Board (Photo: Business Wire) Dr. Tang is a longtime veteran of the medical diagnostic industry. He led OraSure Technologies, Inc. (NASDA
BETHLEHEM, Pa., Nov. 09, 2021 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ:OSUR), a global leader in point-of-care and home diagnostic testing and sample collection technologies, announced today that after almost 21 years of service to the Company, Jack E. Jerrett is retiring as the Company's Senior Vice President, General Counsel, Chief Compliance Officer and Secretary, effective as of December 31, 2021. Agnieszka M. Gallagher, who most recently served as the Chief Ethics and Compliance Officer at Alnylam Pharmaceuticals has been hired by the Company to fill Jack's roles as the new General Counsel, Chief Compliance Officer and Secretary. "Jack has been a stalwart and extremely
Evercore ISI Group analyst Vijay Kumar maintains OraSure Technologies (NASDAQ:OSUR) with a In-Line and lowers the price target from $5.5 to $4.5.
JP Morgan analyst Casey Woodring maintains OraSure Technologies (NASDAQ:OSUR) with a Neutral and lowers the price target from $7 to $6.